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Abstract
Mucosal vaccines can induce mucosal immunity, including antigen-specific secretory IgA 
production, to protect from invasion by pathogens and to neutralize toxins at mucosal surfaces. 
We established an effective antigen-delivering fusion protein, anti-GP2-SA, as a mucosal vaccine. 
The anti-GP2-SA consists of streptavidin (SA) fused to the antigen-binding fragment region from 
a mAb against glycoprotein 2 (GP2), an antigen-uptake receptor specifically expressed on M cells. 
Anti-GP2-SA targets antigen-sampling M cells in the follicle-associated epithelium covering Peyer’s 
patches. Immunofluorescence showed that anti-GP2-SA specifically bound to M cells. Orally 
administered biotinylated ovalbumin peptide (bOVA) conjugated with anti-GP2-SA more efficiently 
induced OVA-specific fecal IgA secretion compared with bOVA alone or bOVA conjugated with 
SA. Furthermore, mice immunized by oral administration of the biotinylated Salmonella enterica 
serovar Typhimurium (S. Typhimurium) lysate conjugated with anti-GP2-SA were significantly better 
protected from subsequent infection by virulent S. Typhimurium than mice treated with the bacterial 
lysate alone or conjugated with SA. These results suggest that anti-GP2-SA-based M-cell-targeting 
vaccines are a novel strategy for inducing efficient mucosal immunity.
Keywords: IgA, M cell, mucosal vaccine, vaccine delivery
Introduction
Mucosal vaccines given via the oral route can induce 
mucosal immunity, such as antigen-specific secretory IgA 
(SIgA) production, as well as systemic immunity (1). By con-
trast, systemic vaccination, for example mumps vaccine, via 
the cutaneous route, will induce only systemic immunity with 
poor mucosal immunity (2). Accordingly, effective mucosal 
vaccines can protect from pathogens before their invasion 
across mucosal barriers and neutralize toxins, ingested or 
generated in the mucosal space by pathogens (3). On the 
other hand, mucosal vaccines have some disadvantages; for 
example, oral vaccines need to resist harsh pH conditions, 
such as pH 1–2 in gastric acid in the stomach, and multiple 
digestive enzymes to reach mucosal immune tissues such 
as Peyer’s patches (PPs) in sufficient amounts. To overcome 
the problem, live attenuated pathogens can be used as oral 
vaccines since they can propagate in the intestine, providing 
adequate immunogenicity even if only a small portion of the 
administered antigen reaches the immune tissue. However, 
attenuated pathogens can give rise to virulent revertants, 
causing adverse side-effects (4). Several studies are under-
way to circumvent the problem of revertants. Safer adjuvants 
are being created by removing harmful structures from patho-
genic antigens (5) on the basis of findings that adjuvants such 
as cholera toxin (CT) can induce efficient mucosal immune 
responses to bystander antigens when they are coadminis-
tered, even when the antigens by themselves cannot induce 
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good immune responses (6). However, in clinical trials it has 
been reported that CT can also induce adverse side-effects 
(7). In addition to the mucosal adjuvants, efforts have been 
made to establish more efficient antigen delivery systems for 
effective mucosal vaccines, such as enteric-coated capsules 
(8), nanoparticles (9) and M-cell-targeting molecules (10).
M cells are located in the follicle-associated epithelium 
overlaying the PP and take up luminal antigens to initiate 
antigen-specific mucosal immune responses (11). Recently, 
several molecules important for M-cell differentiation and 
function have been identified (12–14). In particular, glyco-
protein 2 (GP2) is specifically expressed by M cells among 
the intestinal epithelium and is essential for uptake of type 
I-piliated bacteria for induction of effective mucosal as well 
as systemic antigen-specific immune responses. These find-
ings led us to consider GP2 as a suitable target molecule 
for efficient mucosal vaccine delivery. In support of this idea, 
a previous mucosal vaccine study of M-cell-targeting mol-
ecules suggested that development of novel M-cell-targeting 
mucosal vaccines is a realistic approach (10).
One strategy in efforts to establish efficient targeting vehi-
cles for vaccines has been to fuse recombinant antigen-bind-
ing antibody domains, such as an antigen-binding fragment 
(Fab), with other proteins (15). There are essentially two types 
of recombinant Fab. One is the single-chain variable fragment 
(scFv), composed of the variable fragments of heavy chains 
and light chains connected by a flexible peptide linker. The 
other is disulfide-stabilized Fvs (dsFv), in which the variable 
fragments of heavy and light chains are bound to each other 
by disulfide bonds, as exist within the intact Fab. The advan-
tages of dsFv over scFv are the biological half-life, stability 
to denaturants and temperature (16), and the slow unfolding 
rate that may confer resistance to a short period of adverse 
conditions (17).
Here, we report the construction of a fusion protein of 
streptavidin (SA) with dsFv originating from an anti-GP2 mAb. 
The resulting dsFv-anti-GP2-SA can bind both biotinylated 
antigen and GP2 and, as a consequence, serve as an effi-
cient mucosal vaccine by delivering the antigen to M cells. 
The remarkable effectiveness of the antigen-conjugated 
anti-GP2-SA was demonstrated in mice, which were able to 
respond with antigen-specific SIgA even without adjuvant.
Methods
Animals
Male BALB/cA mice (6–8 weeks old) and C57BL/6 mice 
(5–7 weeks old) were obtained from CLEA Japan. C57BL/6 
back-crossed GP2−/− mice (18) were maintained in the RIKEN 
Yokohama Animal Facility. All animal experiments were per-
formed in accordance with the Guidelines for the Care and 
Use of Laboratory Animals in RIKEN and Institutional Animal 
Care and Use Committee of Yokohama City University 
Graduate School of Supramolecular Biology and Medical Life 
Science.
Antibodies and reagents
The following antibodies were used: rabbit anti-strepta-
vidin (Abcam), anti-rat HRP (Invitrogen), anti-rabbit HRP 
(Invitrogen), Alexa Fluor 488 anti-rat (Invitrogen), Alexa Fluor 
488 anti-rabbit (Invitrogen) biotinylated rabbit IgG (Abcam), 
Alexa Fluor 633 phalloidin (Invitrogen), rhodamine-labeled 
UEA-1 (Vector Laboratories), VectorShield containing DAPI 
(Vector Laboratories). The anti-GP2 mAb (2F11-C3) was 
obtained as described elsewhere (13).
Complementary DNA cloning and plasmid vector 
construction
Anti-GP2 antibody cDNAs were obtained from total RNA 
extracted from a hybridoma producing anti-GP2 antibody 
using the SMARTer PCR cDNA Synthesis Kit (Clontech) 
according to the manufacturer’s instructions. Variable regions 
of Igγ (VH) and Igκ (VL) in the cDNA were amplified and 
sequenced, and then the native signal peptides in the ampli-
cons were replaced with the human IL-6 signal peptide for 
secretion. The VH was connected to a mouse IgG2a CH1 
with its hinge sequence and the SA core sequence (15). 
The VL was connected to a mouse Igκ Cκ sequence. Both 
sequences contained a His Tag embedded in the plasmid 
vector (VH-CH1-SA and VL-Cκ).
Fusion protein expression and purification
A Ni-NTA column was used to purify anti-GP2-SA from 
Hyclone SFM4HEK293 without Biotin (Thermo Scientific) cul-
ture supernatants of 293F cells transfected with the mCH1-SA 
and mIgκ-Cκ.
Structural assessment of anti-GP2-SA and immunostaining
Purified anti-GP2-SA, rat IgG and SA were subjected to 10 
or 7.5% SDS–PAGE. After electrophoresis, gels were directly 
stained with Coomassie Brilliant Blue (CBB) or blotted onto an 
Immobilon-P membrane (Millipore). CBB stained gels were 
decolorized by soaking in reverse osmosis water. Blotted 
membranes were incubated overnight in 2% BSA/skimmed 
milk in PBS for blocking, and then with anti-rat IgG HRP or 
anti-SA antibody. Anti-SA antibody was detected with an anti-
rabbit HRP secondary antibody. Chemical luminescence was 
detected by LAS-3000 (FUJIFILM).
Ligated ileal loop experiment and whole-mount staining 
of PPs
Mice were anesthetized with isoflurane. Ten micrograms of 
anti-GP2 antibody or anti-GP2-SA with biotinylated rabbit-
IgG or SA with biotinylated rabbit-IgG were injected into the 
ligated ileal loop containing a single PP. After incubation for 
10–15 min, the mice were sacrificed and PPs were excised 
from the intestine. Specimens were washed gently and then 
fixed and permeabilized with a Cytofix/Cytoperm kit (BD 
Biosciences). Anti-GP2 antibody-treated specimens were 
incubated with Alexa Fluor 488 anti-rat IgG. The specimens 
treated with anti-GP2-SA or SA plus biotinylated rabbit IgG 
were incubated with Alexa Fluor 488 anti-rabbit IgG. All PP 
specimens were stained with rhodamine-labeled UEA-1 and 
Alexa Fluor 633 phalloidin to detect F-actin. The specimens 
were embedded in a 30% solution of glycerol in PBS and 
analyzed with a confocal laser scanning microscope (Leica 
Microsystems).
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Immunization studies
Ovalbumin peptide (OVA) was biotinylated with Biotin-(AC5)2 
Sulfo-OSu (DOJINDO) according to the manufacturer’s 
instructions. Biotinylated OVA (bOVA) was incubated for 
30 min with SA or anti-GP2-SA to form complexes just before 
administration. Mice were orally immunized three times every 
other day with bOVA (50  μg) or the complexes (50  μg of 
bOVA with 30 μg of SA or anti-GP2-SA in PBS) or PBS alone. 
One, two and three weeks after the final immunization, feces 
were collected, freeze dried and crushed. The crushed feces 
were re-suspended (1 g ml−1) in proteinase inhibitor-contain-
ing PBS and extracted by pestle homogenization and diluted: 
26-fold (Fig. 4) and 23-fold (Supplementary Figure 1, available 
at International Immunology Online). OVA-specific IgA in the 
fecal extracts was analyzed by ELISA using plates coated 
with 1 mg ml−1 OVA. Optical density (OD) was normalized to 
the anti-OVA ELISA titers in fecal extracts from each mouse 
prior to immunization.
Salmonella enterica serovar Typhimurium (S. Typhimurium) 
carrying a nalidixic acid resistance gene (χ3306) was a gift from 
H. Matsui (19) and the fimH deletion mutant of S. Typhimurium 
(fimH− S. Typhimurium) was established elsewhere (13) 
from toxC-harboring S. Typhimurium (a gift from Dr Gordon 
Dougan). An insoluble protein fraction of fimH− S. Typhimurium 
was prepared by repeating freeze-thaw cycles three times 
and extensive washing with PBS. The resulting insoluble pro-
tein fraction was biotinylated and used for complex forma-
tion with SA or anti-GP2-SA. Mice were separated into four 
groups, and mice in each group were orally administered with 
solutions containing the biotinylated insoluble protein fraction 
from 3 × 107 colony forming unit (CFU) of FimH− S. Typhimurium 
alone, or with SA or anti-GP2-SA, or PBS three times every 
other day. Two weeks after the final immunization, feces were 
collected and fecal IgA content in each mouse was examined 
by ELISA using plates coated with the insoluble protein fraction 
of FimH− S. Typhimurium. The mice were then fed with 1 × 107 
CFU of S. Typhimurium χ3306 and survival of treated mice was 
observed at a fixed time each day.
Data analysis
Data are expressed as the mean ± SEM. Statistical sig-
nificance was determined by analysis of variance (Fig. 3A, 
Supplementary Figure  1, available at International 
Immunology Online) or the Holm method (Figs 3B and 4A) 
or the Student’s t-test (Fig. 3C) or log-rank test (Fig. 4B) or 
Pearson’s product–moment correlation coefficient (Fig. 4C).
Results
Establishment of anti-GP2-SA
To establish a mucosal vaccine with novel features, we first 
constructed a recombinant anti-GP2-SA plasmid vector and 
transfected it into 293-F cells. Expressed anti-GP2-SA was 
expected to form a tetramer because SA normally forms 
a tetramer, as shown in Fig. 1(A). Thus, we tested whether 
anti-GP2-SA formed a tetramer possessing the IgG vari-
able regions from the parental anti-GP2 antibody and the SA 
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Fig. 1. Characterization of the recombinant anti-GP2-SA. (A) Schematic model of anti-GP2-SA. (B) CBB staining of anti-GP2-SA. Anti-GP2-SA 
was analyzed by 10% SDS–PAGE under non-reducing (NR) and reducing (R) conditions (2-ME plus boiling). (C and D) Western blotting was 
performed after 7.5% SDS–PAGE under NR conditions as described in Methods. The anti-GP2-SA was detected by anti-rat IgG antibody (C) or 
anti-SA antibody (D). Data are representative of experiments performed at least three times. Rat IgG, purified serum IgG.
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core by CBB staining and western blotting (Fig. 1B–D). The 
theoretical molecular weight of VH-CH1-SA is ~49 000 Da, 
whereas VL-Cκ is ~30 000 Da. CBB staining showed a band 
with the expected molecular weight for the whole anti-GP2-
SA tetramer, about 320 000 Da, under non-reducing condi-
tions, as well as VH-CH1-SA and VL-Cκ monomers when 
the samples were reduced with 2-mercaptoethanol (Fig. 1B). 
In addition, western blotting showed that the anti-GP2-SA 
tetramer contains the rat IgG components and SA core pro-
teins (Fig.  1C and D). These observations confirm that the 
generated anti-GP2-SA had the expected structure.
Anti-GP2-SA delivers biotinylated molecules to PP M cells 
in mice
We next asked whether anti-GP2-SA maintained the capac-
ity to bind GP2 on M cells by using a ligated ileal loop assay 
and whole-mount immunostaining. Anti-GP2-SA conjugated 
with biotinylated rabbit IgG, or SA as a negative control, was 
injected into the lumen of a ligated ileal loop. As shown in 
Fig.  2, anti-rabbit IgG was found to localize on UEA-1+ M 
cells in anti-GP2-SA-injected, but not SA-injected, samples 
(Fig. 2G and K). The fact that anti-GP2-SA administered into 
the intestinal lumen could deliver conjugated rabbit IgG to 
PP M cells raised the possibility that this molecule would 
be a useful vehicle for generating efficient mucosal immune 
responses to biotinylated oral vaccine antigens.
Anti-GP2-SA efficiently induces antigen-specific fecal 
SIgA responses
To test the hypothesis that anti-GP2-SA can effectively 
deliver biotinylated antigen to M cells for efficient induction 
of mucosal immune response, we measured fecal SIgA spe-
cific for various forms of orally administered bOVA. Orally 
administered OVA by itself does not normally induce mucosal 
immune responses (20). As expected, orally administered 
bOVA alone or conjugated with SA did not evoke efficient 
secretion of OVA-specific fecal SIgA (Fig. 3A). By contrast, 
when orally administered as a conjugate with anti-GP2-SA, 
bOVA efficiently induced OVA-specific fecal SIgA secre-
tion (Fig. 3A) and the titer at week 3 was significantly higher 
compared with the groups immunized with SA-bOVA or 
bOVA alone (Fig. 3B). In addition, we confirmed whether the 
effect of anti-GP2-SA seen above evoked through its GP2 
binding by utilizing GP2−/− mice. As expected, administra-
tion of bOVA-anti-GP2-SA to GP2−/− mice barely induced 
OVA-specific fecal SIgA (Supplementary Figure 1, available 
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Fig. 2. Binding of anti-GP2-SA to PP M cells in a ligated ileal loop assay. Ligated ileal loops were injected with anti-GP2 antibody as a posi-
tive control (A–D), complexes of anti-GP2-SA and biotinylated rabbit IgG (E–H) or complexes of SA and biotinylated rabbit IgG as a negative 
control (I–L). Alexa Fluor 633 phalloidin (blue) was used to stain F-actin (A,E,I). M cells are stained with UEA-1 (red) (B,F,J). Anti-GP2 antibody 
was detected with Alexa Fluor 488 anti-rat IgG (green) (C). Rabbit-IgG was detected with Alexa Fluor 488 anti-rabbit IgG (green) (G,K). The 
right-most panels (D,H,L) are the merged images of the left three panels. Note that UEA-1 also reacts with goblet cells so the co-localization is 
incomplete. Scale bar, 50 μm. Results represent at least three specimens in each group.
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at International Immunology Online), indicating that anti-GP2-
SA indeed delivered bOVA in a GP2-dependent manner. 
Interestingly, the OVA-specific fecal SIgA titer induced by 
oral administration of bOVA-anti-GP2-SA was comparable 
in the presence and absence of CT as a mucosal adjuvant 
(Fig. 3C). By contrast, bOVA-anti-GP2-SA without CT group 
showed a higher SIgA titer than the bOVA and CT-treated 
group after 3 weeks (Fig.  3C). These results suggest that 
anti-GP2-SA can induce an efficient SIgA response by deliv-
ering biotinylated antigens to M cells, and that the addition 
of mucosal adjuvant may be dispensable for the anti-GP2-
SA-mediated SIgA response.
Anti-GP2-SA-mediated vaccine delivery can protect 
against S. Typhimurium infection
Since delivery of bOVA to M cells by anti-GP2-SA led to 
induction of an efficient OVA-specific fecal SIgA response, we 
hypothesized that anti-GP2-SA could be a useful mucosal vac-
cine delivery tool. To test the possibility, we asked if anti-GP2-
SA-mediated M-cell delivery of S. Typhimurium vaccine 
antigens could protect mice from subsequent S. Typhimurium 
infection. We used a lysate of fimH− S. Typhimurium as the 
source of vaccine antigens to avoid autonomous delivery of 
antigens to GP2-expressing M cells, since the FimH+ type 1 
pilus is a GP2 ligand (13).
Mice were orally immunized with a biotinylated lysate of 
fimH− S. Typhimurium alone, or conjugated with anti-GP2-
SA or SA, or PBS as a negative control and challenged with 
virulent S. Typhimurium. Two weeks after the final immuniza-
tion, a significant S. Typhimurium-specific fecal IgA response 
was induced only in mice immunized with the biotinylated 
bacterial lysate with anti-GP2-SA (Fig. 4A). Consistently, mice 
vaccinated by this regimen survived significantly longer upon 
subsequent oral challenge with virulent S. Typhimurium than 
mice from the other three groups, where all mice died within 
10 days after infection (Fig. 4B). Furthermore, the fecal SIgA 
content and mouse survival showed a significant positive 
correlation (Fig. 4C, R = 0.56). Taken together, these results 
confirmed that an M-cell-targeting vaccine is a useful tool for 
efficient mucosal vaccination, and that anti-GP2-SA should 
be very useful for this purpose.
Discussion
Mucosal vaccination is theoretically superior to systemic vac-
cination since the former can evoke both mucosal and sys-
temic immunity whereas the later can only induce systemic 
responses (2). However, mucosal vaccination has not been 
widely used because of the difficulty in designing practical vac-
cines. Mucosal vaccines have to survive harsh conditions such 
as the highly acidic gastric environment and intestinal digestive 
enzymes to reach the mucosal immune system. To overcome 
the insufficient immunogenicity because of the small amount of 
residual vaccine surviving the gastrointestinal environment, the 
existing mucosal vaccines utilize attenuated live pathogens, 
which can propagate in the mucosal tissue, or supplementa-
tion of the vaccine with adjuvants to enhance immunogenicity. 
However, these strategies have intrinsic disadvantages for clini-
cal use due to, for example diarrhea, the emergence of virulent 
revertants and adverse side-effects of the adjuvants (4). An 
efficient adjuvant-free vaccine delivery vehicle for the mucosal 
immune system could overcome these problems and would be 
a valuable addition to the vaccine armamentarium.
Fig. 3. Induction of OVA-specific fecal SIgA upon oral immunization of mice with anti-GP2-SA-conjugated bOVA. Mice were orally administered 
with PBS, bOVA, SA-conjugated bOVA or anti-GP2-SA-conjugated bOVA. Fecal SIgA was determined by ELISA as described in Methods. 
(A) OVA-specific SIgA titers. The titers were normalized to the OVA-specific SIgA titer in feces from each mouse before treatment (0 week). 
(B) OVA-specific fecal SIgA titers in each group at week 3. (C) OVA-specific fecal SIgA titers in mice treated with anti-GP2-SA conjugated to 
bOVA in the presence or absence of CT and mixture of bOVA with CT. Data are expressed as the mean ± SEM from five mice per each group. 
*P < 0.05, **P < 0.01.
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To tackle this issue, we chose GP2 as the target for vac-
cine delivery to the mucosal immune system. GP2 is one of 
the most highly expressed apical surface molecules specific 
to PP M cells and serves as a receptor for antigen uptake 
and delivery to the mucosal immune system (13). Moreover, 
a previous report had shown that M cells are a good target 
for induction of antigen-specific mucosal immune responses 
(10).
To design the GP2-targeting vehicle, we took advantage of 
a GP2-specific mAb generated in our laboratory (13). In this 
report, we constructed an anti-GP2-SA fusion protein, in which 
SA, as a receptor for biotinylated antigens, was appended to 
a dsFv from the anti-GP2 antibody. SA was chosen because 
of its remarkably high affinity for biotin (Kd ≈10
–14) and, more 
importantly, since it is very stable under adverse conditions 
such as those causing denaturation (16), making it suitable 
for gastrointestinal administration. In fact, anti-GP2-SA was 
able to survive the gastrointestinal luminal environment to effi-
ciently deliver antigens, bOVA and the biotinylated insoluble 
protein fraction of fimH− S. Typhimurium to PP M cells and to 
induce antigen-specific SIgA responses. These results also 
indicate that the affinity for GP2 of the dsFv in the anti-GP2-SA 
is sufficient to bind to, and be taken up into, PPs via M cells.
Intriguingly, the fecal OVA-specific SIgA titer induced by 
oral bOVA-anti-GP2-SA was comparable in the presence or 
absence of CT as an adjuvant. Although we currently have 
no experimental evidence to explain this observation, one 
possibility is that SA, a bacterial component, could possess 
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Fig. 4. Induction of protective immunity against S. Typhimurium infection by oral immunization with biotinylated S. Typhimurium lysate conju-
gated to anti-GP2-SA. (A) Fecal S. Typhimurium-specific IgA. Mice were orally administered with solutions containing the biotinylated insoluble 
protein fraction of fimH- S. Typhimurium (BP) alone, or with SA or anti-GP2-SA, or PBS three times as described in Methods. Feces were col-
lected 2 weeks after the final immunization and fecal IgA specific to the insoluble protein fraction of fimH- S. Typhimurium for each mouse was 
determined by ELISA as described in Methods. Results are derived from six mice per each group and shown as mean ± SEM. (B) Survival 
curves of S. Typhimurium-infected mice. Mice immunized in A were fed 1 × 107 CFU of S. Typhimurium χ3306 and the survival of treated mice 
was observed at a fixed time every day. (C) Correlation of fecal SIgA concentration (OD) in A and survival (days) in B of each mouse. Kaplan–
Meier survival curves were constructed and analyzed by a log-rank test. Data were analyzed by the Holm method (B) or Pearson’s product–
moment correlation coefficient (C). *P < 0.05, **P < 0.01, ***P < 0.001.
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some degree of adjuvant activity. Alternatively, commen-
sal microbes taken up in parallel with anti-GP2-SA by M 
cells may serve as natural adjuvants to enhance immune 
responses against bOVA. Further studies will be required to 
clarify the point.
In this study, we introduce anti-GP2-SA as a novel adjuvant-
free mucosal vaccine delivery tool that can efficiently induce 
mucosal SIgA responses. Our results also indicate that M-cell-
targeting vaccination should be an effective and safe strat-
egy, in that inactivated vaccines can be delivered in sufficient 
amounts to evoke protective immunity against pathogens.
Supplementary data
Supplementary data are available at International Immunology 
Online.
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